Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBE trial of rilpivirine backbone substitution in virologically suppressed HIV-1 adults
2013-002573-22Phase 3Active
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rilpivirine in human immunodeficiency virus infection (HIV), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Proportion of patients with HIV-RNA <50 copies/mL at 24 weeks. Started Jun 2013; status: active.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-002573-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002573-22.